adults younger than 18 or older than 65 years adults already vaccinated with other vaccine then janssen previously had a covid-19 infection history of allergic reaction likely to be exacerbated by any component of study vaccines (e.g. hypersensitivity to the active substance or any of the ingredients of the janssen/pfizer/moderna vaccine). adults that are pregnant or have a wish to become pregnant within 6 months currently being treated for cancer severe kidney failure or dialyses dependent status after organ-, stem cell- or bone marrow transplantation use of immunosuppressant's epilepsy hiv bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding of bruising following injections of vene puncture continuous use of anticoagulants, such as coumarins (e.g. acenocoumarol) or novel oral anticoagulants (i.e. apixaban, dabigatran etc). participants who are currently participating in another research trial. all regular contra-indications of the vaccines will be applied.

adults younger than 18 or older than 65 years adults already vaccinated with other vaccine then janssen previously had a covid-19 infection history of allergic reaction likely to be exacerbated by any component of study vaccines (e.g. hypersensitivity to the active substance or any of the ingredients of the janssen/pfizer/moderna vaccine). adults that are pregnant or have a wish to become pregnant within 6 months currently being treated for cancer severe kidney failure or dialyses dependent status after organ-, stem cell- or bone marrow transplantation use of immunosuppressant's epilepsy hiv bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding of bruising following injections of vene puncture continuous use of anticoagulants, such as coumarins (e.g. acenocoumarol) or novel oral anticoagulants (i.e. apixaban, dabigatran etc). participants who are currently participating in another research trial. all regular contra-indications of the vaccines will be applied.

1. adults younger than 18 or older than 65 years 2. adults already vaccinated with other vaccine then janssen 3. previously had a covid-19 infection 4. history of allergic reaction likely to be exacerbated by any component of study vaccines (e.g. hypersensitivity to the active substance or any of the ingredients of the janssen/pfizer/moderna vaccine). 5. adults that are pregnant or have a wish to become pregnant within 6 months 6. currently being treated for cancer 7. severe kidney failure or dialyses dependent 8. status after organ-, stem cell- or bone marrow transplantation 9. use of immunosuppressant's 10. epilepsy 11. hiv 12. bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding of bruising following injections of vene puncture 13. continuous use of anticoagulants, such as coumarins (e.g. acenocoumarol) or novel oral anticoagulants (i.e. apixaban, dabigatran etc). 14. participants who are currently participating in another research trial. 15. all regular contra-indications of the vaccines will be applied.

1. adults younger than 18 or older than 65 years 2. adults already vaccinated with other vaccine then janssen 3. previously had a covid-19 infection 4. history of allergic reaction likely to be exacerbated by any component of study vaccines (e.g. hypersensitivity to the active substance or any of the ingredients of the janssen/pfizer/moderna vaccine). 5. adults that are pregnant or have a wish to become pregnant within 6 months 6. currently being treated for cancer 7. severe kidney failure or dialyses dependent 8. status after organ-, stem cell- or bone marrow transplantation 9. use of immunosuppressant's 10. epilepsy 11. hiv 12. bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding of bruising following injections of vene puncture 13. continuous use of anticoagulants, such as coumarins (e.g. acenocoumarol) or novel oral anticoagulants (i.e. apixaban, dabigatran etc). 14. participants who are currently participating in another research trial. 15. all regular contra-indications of the vaccines will be applied.

1. adults younger than 18 or older than 65 years 2. adults already vaccinated (with prime or/and boost vaccine) 3. previously had a covid-19 infection 4. history of allergic reaction likely to be exacerbated by any component of study vaccines (e.g. hypersensitivity to the active substance or any of the ingredients of the janssen/pfizer/moderna vaccine). 5. adults that are pregnant or have a wish to become pregnant within 6 months 6. currently being treated for cancer 7. severe kidney failure or dialyses dependent 8. status after organ-, stem cell- or bone marrow transplantation 9. use of immunosuppressant's 10. epilepsy 11. hiv 12. bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding of bruising following injections of vene puncture 13. continuous use of anticoagulants, such as coumarins (e.g. acenocoumarol) or novel oral anticoagulants (i.e. apixaban, dabigatran etc). 14. participants who are currently participating in another research trial. 15. all regular contra-indications of the vaccines will be applied.

1. adults younger than 18 or older than 65 years 2. adults already vaccinated (with prime or/and boost vaccine) 3. previously had a covid-19 infection 4. history of allergic reaction likely to be exacerbated by any component of study vaccines (e.g. hypersensitivity to the active substance or any of the ingredients of the janssen/pfizer/moderna vaccine). 5. adults that are pregnant or have a wish to become pregnant within 6 months 6. currently being treated for cancer 7. severe kidney failure or dialyses dependent 8. status after organ-, stem cell- or bone marrow transplantation 9. use of immunosuppressant's 10. epilepsy 11. hiv 12. bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding of bruising following injections of vene puncture 13. continuous use of anticoagulants, such as coumarins (e.g. acenocoumarol) or novel oral anticoagulants (i.e. apixaban, dabigatran etc). 14. participants who are currently participating in another research trial. 15. all regular contra-indications of the vaccines will be applied.